Abstract
ECOG-ACRIN E1505 was a phase III randomized trial of adjuvant chemotherapy +/-bevacizumab for patients with Stage IB (>4cm) – IIIA NSCLC. We sought to estimate the incidence/risk factors for brain recurrence as compared to extracranial recurrences (ECR).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
